Trial reportAntimicrobial agents and chemotherapy2004
Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.
Trial report in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters.Journal of biopharmaceutical statistics · 2008Trial
- Lopinavir/Ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy.Journal of clinical pharmacology · 2007Trial
- Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.Journal of pharmacokinetics and pharmacodynamics · 2007Trial
- Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.British journal of clinical pharmacology · 2005Trial
- High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.Clinical pharmacokinetics · 2005Trial
- Just a Reflection: Does Drug Repurposing Perpetuate Sex-Gender Bias in the Safety Profile?Pharmaceuticals (Basel, Switzerland) · 2021Review
- Caring for women living with HIV: gaps in the evidence.Journal of the International AIDS Society · 2013Review
- Clinical pharmacokinetics of antiretroviral drugs in older persons.Expert opinion on drug metabolism & toxicology · 2013Review
- Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.AIDS research and treatment · 2012Article
- Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.Therapeutic drug monitoring · 2011Article
- Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART.European journal of clinical pharmacology · 2009Article
- Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus.British journal of clinical pharmacology · 2008Article
- Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years.Antimicrobial agents and chemotherapy · 2006Article
- Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents.Current HIV/AIDS reports · 2006Review
- Differential bidirectional transfer of indinavir in the isolated perfused human placenta.Antimicrobial agents and chemotherapy · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Indinavir is currently used at a fixed dose of 800 mg either three times a day or twice a day in combination with 100 mg of ritonavir. Dosage individualization based on plasma concentration monitoring might, however, be indicated. This study aimed to assess the pharmacokinetic profile of indinavir in patients infected with human immunodeficiency virus to characterize interpatient and intrapatient variability and to build up a Bayesian approach for dosage adaptation. A population analysis was performed with the NONMEM computer program with 569 plasma samples from a cohort of 239 unselected patients receiving indinavir. A one-compartment model with first-order absorption was adapted, and the influences of clinical characteristics on oral clearance (CL) and distribution volume (V) were examined. Predicted average drug exposure and trough and peak concentrations were derived for each patient and correlated with efficacy and toxicity markers. The population estimates of CL were 32.4 liters/h for female and 42.0 liters/h for male patients; oral V was 65.7 liters; and the rate constant of absorption (K(a)) was 1.0 h(-1). CL decreased by 63% with ritonavir intake and was moderately correlated to body weight. Both interpatient variability, best assigned to oral CL (coefficient of variation [CV], 39%) and K(a) (CV, 67%), and intrapatient variability were large (CV, 41%; standard deviation, 670 microg/liter). In conclusion, initial indinavir dosage should be decided according to ritonavir intake and sex, prior to plasma concentration measurements. The high interpatient pharmacokinetic variability represents an argument for therapeutic drug monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.